What is it about?
we propose Hyaluronic acid - 2-Deoxy-D-Glucose (HA-2DG) conjugate as a novel drug for the treatment of COVID-19
Featured Image
Why is it important?
The present study is to propose a novel and efficient drug for COVID-19 disease, using tumor anti-metabolite drug, 2-Deoxy-Dglucose (2DG), covalently linking it at a specific position with the Hyaluronic acid (HA) to afford HA-2DG conjugate to increase its bioavailability, safe, improve its localization, controlled release in the body, enhance its overall efficiency, and eliminate or reduce systemic toxicity if any.
Perspectives
To develop a drug conjugate, 2DG-HA from hyaluronic acid (HA) biomaterial, which is present in extracellular matrices and the synovial fluid of joints, and 2DG, to increase its bioavailability, stability, localization, controlled release, enhance the efficacy and safety, and devoid of any side effects. Alternate Strategies
Professor Aroulmoji Vincent
Mahendra Educational Trust
Read the Original
This page is a summary of: Hyaluronic Acid - 2-Deoxy-D-Glucose Conjugate Act as a Promising Targeted Drug Delivery Option for the Treatment of COVID-19, International Journal of Advanced Science and Engineering, May 2021, International Journal of Advanced Science and Engineering(IJASE),
DOI: 10.29294/ijase.7.4.2021.1995-2005.
You can read the full text:
Contributors
The following have contributed to this page
